Detalhe da pesquisa
1.
Durable polymer versus biodegradable polymer drug-eluting stents in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: a post hoc analysis of the HOST-REDUCE-POLYTECH-ACS trial.
EuroIntervention
; 18(11): e910-e919, 2022 Dec 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36000257
2.
Two-Year Safety and Efficacy of Biodegradable Polymer Drug-Eluting Stent Versus Second-Generation Durable Polymer Drug-Eluting Stent in Patients With Acute Myocardial Infarction: Data from the Korea Acute Myocardial Infarction Registry (KAMIR).
Clin Cardiol
; 39(5): 276-84, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-27028303
3.
Echogenicity as a surrogate for bioresorbable everolimus-eluting scaffold degradation: analysis at 1-, 3-, 6-, 12- 18, 24-, 30-, 36- and 42-month follow-up in a porcine model.
Int J Cardiovasc Imaging
; 31(3): 471-82, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25627777
4.
Harmonizing Optimal Strategy for Treatment of coronary artery diseases--comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial.
Trials
; 16: 409, 2015 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26374625
5.
Scaffold and edge vascular response following implantation of everolimus-eluting bioresorbable vascular scaffold: a 3-year serial optical coherence tomography study.
JACC Cardiovasc Interv
; 7(12): 1361-9, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25457053